Loading, please wait ...


News Analytics

6401e7017fd5aa7ed59e91b4399a99ea52339ca3 480x270 jpg?fit=crop&auto=format.
The FDA has granted approval to the VENTANA ALK (D5F3) CDx Assay as a companion diagnostic (CDx) to identify patients with ALK-positive non–small cell lung cancer (NSCLC) who may be eligible for treatment with the recently approved ALK inhibitor lorlatinib (Lorbrena), announced Roche, in a press release.1 Approval of this CDx makes the VENTANA ALK CDx Assay the ...
Google

Subject Matter

  • Healthcare 67.14%
    • Hospitals, doctors and medical care 100.00%
  • Science and technology 32.86%

Emotional Reaction

Sentiment

Positive

Neutral

Negative

Definitions